

# REFERENCES

---

---

1. Jain A, Gulbake A, Jain A, Shilpi S, Hurkat P, Kashaw S, et al. Development and validation of the HPLC method for simultaneous estimation of paclitaxel and topotecan. *Journal of chromatographic science*. 2013;52 (7):697-703.
2. Lee J-Y, Kim HS, Song Y-S. Genistein as a potential anticancer agent against ovarian cancer. *Journal of traditional and complementary medicine*. 2012;2(2):96-104.
3. Cavallaro G, Licciardi M, Caliceti P, Salmaso S, Giammona G. Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug. *European journal of pharmaceutics and biopharmaceutics*. 2004;58(1):151-9.
4. Rusin A, Krawczyk Z, Gryniewicz G, Gogler A, Zawisza-Puchalka J, Szeja W. Synthetic derivatives of genistein, their properties and possible applications. *Acta Biochimica Polonica*. 2010;57(1):23-34.
5. Müller R, Radtke M, Wissing S. Nanostructured lipid matrices for improved microencapsulation of drugs. *International journal of pharmaceutics*. 2002;242(1):121-8.
6. Radtke M, Muller R, editors. Comparison of structural properties of solid lipid nanoparticles (SLN) versus other lipid particles. *Proc Int Symp Control Rel Bioact Mater*; 2000.
7. Das S, Ng WK, Tan RB. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? *European Journal of Pharmaceutical Sciences*. 2012;47(1):139-51.
8. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. *Advanced drug delivery reviews*. 2002;54:S131-S55.

9. Shah NV, Seth AK, Balaraman R, Aundhia CJ, Maheshwari RA, Parmar GR. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: design and in vivo study. *Journal of advanced research*. 2016;7(3):423-34.
10. Bala I, Hariharan S, Kumar MR. PLGA nanoparticles in drug delivery: the state of the art. *Critical Reviews™ in Therapeutic Drug Carrier Systems*. 2004;21(5).
11. Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, Feron O, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. *Journal of Controlled Release*. 2009;133(1):11-7.
12. Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. *International journal of pharmaceutics*. 2006;325(1):172-9.
13. Gazori T, Khoshayand MR, Azizi E, Yazdizade P, Nomani A, Haririan I. Evaluation of Alginate/Chitosan nanoparticles as antisense delivery vector: Formulation, optimization and in vitro characterization. *Carbohydrate Polymers*. 2009;77(3):599-606.
14. Vardhan H, Mittal P, Adena SKR, Mishra B. Long-circulating polyhydroxybutyrate-co-hydroxyvalerate nanoparticles for tumor targeted docetaxel delivery: Formulation, optimization and in vitro characterization. *European Journal of Pharmaceutical Sciences*. 2017;99:85-94.
15. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. *CA: a cancer journal for clinicians*. 2018.
16. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. *Nature materials*. 2013;12(11):991.
17. Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P. Design, functionalization strategies and biomedical applications of targeted

- biodegradable/biocompatible polymer-based nanocarriers for drug delivery. *Chemical Society Reviews*. 2013;42(3):1147-235.
18. Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. *Journal of controlled release*. 2008;126(3):187-204.
19. Ma Y, Nolte RJ, Cornelissen JJ. Virus-based nanocarriers for drug delivery. *Advanced drug delivery reviews*. 2012;64(9):811-25.
20. Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. *Pharmacology & therapeutics*. 2006;112(3):630-48.
21. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. *Journal of controlled release*. 2010;148(2):135-46.
22. Ali I, Nadeem Lone M, Suhail M, Danish Mukhtar S, Asnin L. Advances in nanocarriers for anticancer drugs delivery. *Current medicinal chemistry*. 2016;23(20):2159-87.
23. Khodabandehloo H, Zahednasab H, Hafez AA. Nanocarriers usage for drug delivery in cancer therapy. *Iranian journal of cancer prevention*. 2016;9(2).
24. Wissing S, Kayser O, Müller R. Solid lipid nanoparticles for parenteral drug delivery. *Advanced drug delivery reviews*. 2004;56(9):1257-72.
25. Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation,

- physicochemical characterization and in vitro anti-tumoral activity. *Journal of Controlled Release*. 2002;83(2):273-86.
26. Mu L, Feng S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS. *Journal of controlled release*. 2003;86(1):33-48.
27. Lim HJ, Nam HY, Lee BH, Kim DJ, Ko JY, Park Js. A Novel Technique for Loading of Paclitaxel-PLGA Nanoparticles onto ePTFE Vascular Grafts. *Biotechnology progress*. 2007;23(3):693-7.
28. Danhier F, Vroman B, Lecouturier N, Crockart N, Pourcelle V, Freichels H, et al. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. *Journal of Controlled Release*. 2009;140(2):166-73.
29. Xu W, Lee M-K. Development and evaluation of lipid nanoparticles for paclitaxel delivery: a comparison between solid lipid nanoparticles and nanostructured lipid carriers. *Journal of Pharmaceutical Investigation*. 2015;45(7):675-80.
30. Pandita D, Ahuja A, Velpandian T, Lather V, Dutta T, Khar R. Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique. *Die Pharmazie-An International Journal of Pharmaceutical Sciences*. 2009;64(5):301-10.
31. Zhao L, Feng S-S. Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. *Journal of pharmaceutical sciences*. 2010;99(8):3552-60.

32. Pan J, Feng S-S. Targeted delivery of paclitaxel using folate-decorated poly (lactide)-vitamin E TPGS nanoparticles. *Biomaterials*. 2008;29(17):2663-72.
33. Kim J-H, Kim Y, Bae KH, Park TG, Lee JH, Park K. Tumor-targeted delivery of paclitaxel using low density lipoprotein-mimetic solid lipid nanoparticles. *Molecular pharmaceutics*. 2015;12(4):1230-41.
34. Chirio D, Gallarate M, Peira E, Battaglia L, Muntoni E, Riganti C, et al. Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment. *European Journal of Pharmaceutics and Biopharmaceutics*. 2014;88(3):746-58.
35. Lee M-K, Lim S-J, Kim C-K. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. *Biomaterials*. 2007;28(12):2137-46.
36. Jia L, Zhang D, Li Z, Duan C, Wang Y, Feng F, et al. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. *Colloids and Surfaces B: Biointerfaces*. 2010;80(2):213-8.
37. Yang Z, Kulkarni K, Zhu W, Hu M. Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME. *Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)*. 2012;12(10):1264-80.
38. Patel NV, Sheth NR, Mohddesi B. Formulation and Evaluation of Genistein–A Novel Isoflavone Loaded Chitosan and Eudragit® Nanoparticles for Cancer Therapy.

- Materials Today: Proceedings. 2015;2(9):4477-82.
39. Kim JT, Barua S, Kim H, Hong S-C, Yoo S-Y, Jeon H, et al. Absorption study of genistein using solid lipid microparticles and nanoparticles: control of oral bioavailability by particle sizes. *Biomolecules & therapeutics*. 2017;25(4):452.
40. Tang J, Xu N, Ji H, Liu H, Wang Z, Wu L. Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment. *International journal of nanomedicine*. 2011;6:2429.
41. Chen Q-H, Yu K, Zhang X, Chen G, Hoover A, Leon F, et al. A new class of hybrid anticancer agents inspired by the synergistic effects of curcumin and genistein: Design, synthesis, and anti-proliferative evaluation. *Bioorganic & medicinal chemistry letters*. 2015;25(20):4553-6.
42. Wu B, Liang Y, Tan Y, Xie C, Shen J, Zhang M, et al. Genistein-loaded nanoparticles of star-shaped diblock copolymer mannitol-core PLGA-TPGS for the treatment of liver cancer. *Materials Science and Engineering: C*. 2016;59:792-800.
43. Zou T, Gu L. TPGS emulsified zein nanoparticles enhanced oral bioavailability of daidzin: in vitro characteristics and in vivo performance. *Molecular pharmaceutics*. 2013;10(5):2062-70.
44. Andrade LM, de Fátima Reis C, Maione-Silva L, Anjos JLV, Alonso A, Serpa RC, et al. Impact of lipid dynamic behavior on physical stability, in vitro release and skin permeation of genistein-loaded lipid nanoparticles. *European Journal of Pharmaceutics and Biopharmaceutics*. 2014;88(1):40-7.

45. Tiyaaboonchai W, Madhusudhan B. Fabrication and characterization of genistein encapsulated poly (D, L) lactic acid nanoparticles for pharmaceutical application. *Current Nanoscience*. 2013;9(2):293-302.
46. Negi LM, Jaggi M, Talegaonkar S. A logical approach to optimize the nanostructured lipid carrier system of irinotecan: efficient hybrid design methodology. *Nanotechnology*. 2012;24(1):015104.
47. Negi LM, Jaggi M, Talegaonkar S. Development of protocol for screening the formulation components and the assessment of common quality problems of nanostructured lipid carriers. *International journal of pharmaceutics*. 2014;461(1):403-10.
48. Guideline IHT. *Pharmaceutical Development Q8 (R2)*. Current step. 2009;4.
49. Vuddanda PR, Rajamanickam VM, Yaspal M, Singh S. Investigations on agglomeration and haemocompatibility of vitamin E TPGS surface modified berberine chloride nanoparticles. *BioMed research international*. 2014;2014.
50. Vijayakumar MR, Kumari L, Patel KK, Vuddanda PR, Vajanthri KY, Mahto SK, et al. Intravenous administration of trans-resveratrol-loaded TPGS-coated solid lipid nanoparticles for prolonged systemic circulation, passive brain targeting and improved in vitro cytotoxicity against C6 glioma cell lines. *RSC Advances*. 2016;6(55):50336-48.
51. Coward L, Barnes NC, Setchell KD, Barnes S. Genistein, daidzein, and their beta.-glycoside conjugates: antitumor isoflavones in soybean foods from American and Asian diets. *Journal of Agricultural and Food Chemistry*. 1993;41(11):1961-7.

52. Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. *Cancer research*. 2010;0008-5472. CAN-09-1947.
53. Zohri M, Gazori T, Mirdamadi S, Asadi A, Haririan I. Polymeric nanoparticles: production, Applications and advantage. *Internet J Nanotechnol*. 2009;3(1).
54. Singare DS, Marella S, Gowthamrajan K, Kulkarni GT, Vooturi R, Rao PS. Optimization of formulation and process variable of nanosuspension: an industrial perspective. *International journal of pharmaceutics*. 2010;402(1):213-20.
55. Singh B, Dahiya M, Saharan V, Ahuja N. Optimizing drug delivery systems using systematic" design of experiments." Part II: retrospect and prospects. *Critical Reviews™ in Therapeutic Drug Carrier Systems*. 2005;22(3).
56. Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic" design of experiments." Part I: fundamental aspects. *Critical Reviews™ in Therapeutic Drug Carrier Systems*. 2005;22(1).
57. Fontell K. Liquid crystallinity in lipid-water systems. *Molecular Crystals and Liquid Crystals*. 1981;63(1):59-82.
58. Yadav SK, Khan G, Bansal M, Vardhan H, Mishra B. Screening of Ionically Crosslinked Chitosan-Tripolyphosphate Microspheres Using Plackett-Burman Factorial Design for the Treatment of Intrapocket Infections. *Drug Development and Industrial Pharmacy*. 2017 (just-accepted):1-53.
59. Bender EA, Adorne MD, Colomé LM, Abdalla DS, Guterres SS, Pohlmann AR. Hemocompatibility of poly ( $\epsilon$ -caprolactone) lipid-core nanocapsules stabilized with



- polysorbate 80-lecithin and uncoated or coated with chitosan. *International journal of pharmaceutics*. 2012;426(1):271-9.
60. Schlosser PM, Borghoff SJ, Coldham NG, David JA, Ghosh SK. Physiologically-Based Pharmacokinetic Modeling of Genistein in Rats, Part I: Model Development. *Risk analysis*. 2006;26(2):483-500.
61. Guideline IHT, editor *Validation of analytical procedures: text and methodology Q2 (R1)*. International Conference on Harmonization, Geneva, Switzerland; 2005.
62. Patel RR, Khan G, Chaurasia S, Kumar N, Mishra B. Rationally developed core-shell polymeric-lipid hybrid nanoparticles as a delivery vehicle for cromolyn sodium: implications of lipid envelop on in vitro and in vivo behaviour of nanoparticles upon oral administration. *RSC Advances*. 2015;5(93):76491-506.
63. Sharma N, Madan P, Lin S. Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: A co-surfactant study. *asian journal of pharmaceutical sciences*. 2016;11(3):404-16.
64. Ekambaram P, Sathali AAH. Formulation and evaluation of solid lipid nanoparticles of ramipril. *Journal of Young Pharmacists*. 2011;3(3):216-20.
65. Velmurugan R, Selvamuthukumar S. Development and optimization of ifosfamide nanostructured lipid carriers for oral delivery using response surface methodology. *Applied Nanoscience*. 2016;6(2):159-73.
66. Constantinou C, Papas A, Constantinou AI. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. *International journal of cancer*.

- 2008;123(4):739-52.
67. Guo Y, Chu M, Tan S, Zhao S, Liu H, Otieno BO, et al. Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance. *Molecular pharmaceutics*. 2013;11(1):59-70.
68. Lasoń E, Sikora E, Ogonowski J. Influence of process parameters on properties of Nanostructured Lipid Carriers (NLC) formulation. *Acta Biochim Pol*. 2013;60(4):773-7.
69. Lawrence XY, Amidon G, Khan MA, Hoag SW, Polli J, Raju G, et al. Understanding pharmaceutical quality by design. *The AAPS journal*. 2014;16(4):771.
70. Högman CF, Hedlund K, Sahlestrom Y. Red Cell Preservation in Protein-Poor Media: III. Protection Against in vitro Hemolysis. *Vox sanguinis*. 1981;41(5-6):274- 81.
71. Mishra B, Padaliya R, Patel RR. Exemestane encapsulated vitamin E-TPGS–polymeric nanoparticles: preparation, optimization, characterization, and in vitro cytotoxicity assessment. *Artificial cells, nanomedicine, and biotechnology*. 2017;45(3):522-34.
72. Bian Q, Liu J, Tian J, Hu Z. Binding of genistein to human serum albumin demonstrated using tryptophan fluorescence quenching. *International journal of biological macromolecules*. 2004;34(5):275-9.
73. Song KC, Lee HS, Choung IY, Cho KI, Ahn Y, Choi EJ. The effect of type of organic phase solvents on the particle size of poly (d, l-lactide-co-glycolide) nanoparticles. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*. 2006;276(1):162-7.

74. Jeong B, Bae YH, Lee DS, Kim SW. Biodegradable block copolymers as injectable drug-delivery systems. *Nature*. 1997;388(6645):860-2.
75. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. *Journal of controlled release*. 2001;70(1):1-20.